June Park

Dr. June Park

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
JPJune Park
June Park
JSJaeseung Shin
Jaeseung Shin
IMIn Kyung Min
In Kyung Min
HBHeejin Bae
Heejin Bae
YKYeo-Eun Kim
Yeo-Eun Kim
YCYong Eun Chung
Yong Eun Chung
Park J, et al. Korean J Radiol. 2022 Jan;23:e19. https://doi.org/10.3348/kjr.2021.0683

1 January 2024 in Investigative Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
HLHyunji Lee
Hyunji Lee
HBHeejin Bae
Heejin Bae
JYJa Kyung Yoon
Ja Kyung Yoon
JPJune Park
June Park
YCYong Eun Chung
Yong Eun Chung
Lee H, et al. Investig Magn Reson Imaging. 2024 Mar;28(1):27-35. https://doi.org/10.13104/imri.2023.0020

1 January 2023 in Journal of the Korean Society of Radiology
Verified
Journal Article
Open access
PDF file
HHHyuk Gi Hong
Hyuk Gi Hong
YCYong Eun Chung
Yong Eun Chung
JPJune Park
June Park
YKYeo Eun Kim
Yeo Eun Kim
홍혁기, et al. J Korean Soc Radiol. 2023 May;84:e55. https://doi.org/10.3348/jksr.2022.0114

20 February 2024 in Diagnostic and Interventional Radiology
Verified
Journal Article
Open access
SCSeo-Bum Cho
Seo-Bum Cho
YKYeun-Yoon Kim
Yeun-Yoon Kim
JPJune Park
June Park
HSHye Jung Shin
Hye Jung Shin
To examine the diagnostic performance for the longitudinal extent of extrahepatic bile duct (EHD) cancer on computed tomography (CT) after biliary drainage (BD) and investigate the appropriate timing of magnetic resonance imaging (MRI) acquisition. This retrospective study included patients who underwent curative-intent surgery for EHD cancer and CT pre- and post-BD between November 2005 and June 2021. The biliary segment-wise longitudinal tumor extent was evaluated according to the 2019 Korean Society of Abdominal Radiology consensus recommendations, with pre-BD CT, post-BD CT, and both pre- and post-BD CT. The performance for tumor detectability was compared using GEEs. When preoperative MRI was performed, patients were divided into two subgroups according to the timing of MRI with respect to BD, and the performance of MRI obtained pre- and post-BD was compared. In 105 patients (mean age: 67 ± 8 years; 74 men and 31 women), the performance for tumor detectability was superior using both CT scans compared with using post-BD CT alone (reader 1: sensitivity, 72.6% vs. 64.6%, P < 0.001; specificity, 96.9% vs. 94.8%, P = 0.063; reader 2: sensitivity, 77.2% vs. 72.9%, P = 0.126; specificity, 97.5% vs. 94.2%, P = 0.003), and it was comparable with using pre-BD CT alone. In biliary segments with a catheter, higher sensitivity and specificity were observed using both CT scans than using post-BD CT (reader 1: sensitivity, 74.4% vs. 67.5%, P = 0.006; specificity, 92.4% vs. 88.0%, P = 0.068; reader 2: sensitivity, 80.5% vs. 74.4%, P = 0.013; specificity, 94.3% vs. 88.0%, P = 0.016). Post-BD MRI (n = 30) exhibited a comparable performance to pre-BD MRI (n = 55) (reader 1: sensitivity, 77.9% vs. 75.0%, P = 0.605; specificity, 97.2% vs. 94.9%, P = 0.256; reader 2: sensitivity, 73.2% vs. 72.6%, P = 0.926; specificity, 98.4% vs. 94.9%, P = 0.068). Pre-BD CT provided better diagnostic performance in the preoperative evaluation of EHD cancer. The longitudinal tumor extent could be accurately assessed with post-BD MRI, which was similar to pre-BD MRI. The acquisition of pre-BD CT could be beneficial for the preoperative evaluation of EHD cancer when BD is planned. Post-BD MRI would not be significantly affected by BD in terms of the diagnostic performance of the longitudinal tumor extent.

10 September 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
JPJune Park
June Park
DKDong Kyu Kim
Dong Kyu Kim
SLSeungsoo Lee
Seungsoo Lee
SHShin Hye Hwang
Shin Hye Hwang
Background: There is little evidence available regarding the long-term tumor response after transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC). Aim: To identify preprocedural predictive factors for achieving a 5-year complete response (CR) following TARE in patients with HCC. Methods: This retrospective study included 37 patients with treatment-naïve HCC who underwent TARE between January 2016 and December 2019 and were followed for at least 5 years. Tumor characteristics—including maximum diameter, number of main lesions, presence of satellite nodules, and portal vein thrombosis—were evaluated using preprocedural liver dynamic magnetic resonance imaging. Treatment response was assessed according to the modified Response Evaluation Criteria in Solid Tumors. Multivariate logistic regression analyses were performed to identify factors associated with tumor response following TARE. Results: Thirty-seven patients (median age, 64 years) were categorized into two groups: (1) the CR group (n = 9), consisting of patients without tumor recurrence for 5 years and without additional treatment; and (2) the non-CR group (n = 28), consisting of patients who required additional treatment because of residual or recurrent viable tumors. Tumors in the non-CR group had significantly larger diameters compared with those in the CR group (9.8 cm vs. 5.9 cm, p = 0.006). In multivariable analysis, a tumor diameter > 7 cm was the only factor significantly associated with tumor recurrence (odds ratio = 21.277, p = 0.010). Portal vein thrombosis did not reach statistical significance (odds ratio = 9.779, p = 0.063). Conclusions: Tumor diameter > 7 cm is a significant predictor of tumor recurrence within 5 years after TARE for HCC. This finding may support a more individualized post-TARE management approach, potentially allowing clinicians to avoid overtreatment and adopt a watchful waiting strategy for selected patients.

15 July 2026 in Korean Journal of Abdominal Radiology
Verified
Journal Article
Open access
JPJune Park
June Park
TCTaek Chung
Taek Chung
Hepatic involvement in systemic amyloidosis is relatively common at autopsy but is rarely the dominant clinical presentation, and its cross-sectional imaging features are often nonspecific. We report a case of biopsy-proven systemic amyloidosis in a 55-year-old woman in whom radiologic hepatic abnormalities were identified more than one year before the development of overt renal dysfunction, and in whom a heterogeneous parenchymal enhancement pattern on cross-sectional imaging was initially interpreted as a primary vascular disorder of the liver with perfusion abnormality, with hereditary hemorrhagic telangiectasia (HHT) and portosinusoidal vascular disease (PSVD) considered the leading differential diagnoses. Dynamic contrast-enhanced CT and gadoxetic acid–enhanced MRI showed heterogeneous arterial-phase parenchymal enhancement with hepatic arterial hypertrophy and a relatively small left portal vein, but no surface nodularity, splenomegaly, or other findings of portal hypertension. Percutaneous biopsy of the right hepatic lobe demonstrated portal lymphocytic infiltration with marked eosinophils and irregular sinusoidal dilatation, without histologic features of cirrhosis. Approximately one year later, the patient developed progressive renal dysfunction, and renal biopsy revealed extensive glomerular and arterial amyloid deposition with apple-green birefringence on Congo red staining under polarized light. Retrospective re-evaluation of the prior liver biopsy with Congo red staining demonstrated amyloid deposition confined to the walls of blood vessels. The systemic workup favored AA (secondary) amyloidosis. This case illustrates that hepatic amyloidosis with vessel-wall–predominant deposition may mimic primary vascular disorders of the liver on cross-sectional imaging and should be considered when heterogeneous parenchymal perfusion is encountered in the absence of definite cirrhosis.